Aytu BioPharma Dividenden en inkoop
Dividend criteriumcontroles 0/6
Aytu BioPharma heeft geen dividenduitkeringen gedaan.
Belangrijke informatie
n/a
Dividendrendement
-63.1%
Terugkoop Rendement
| Totaal aandeelhoudersrendement | -63.1% |
| Toekomstig dividendrendement | n/a |
| Dividendgroei | n/a |
| Volgende betaaldatum dividend | n/a |
| Ex-dividenddatum | n/a |
| Dividend per aandeel | n/a |
| Uitbetalingsratio | n/a |
Recente updates van dividend en inkoop
Geen updates
Recent updates
Narratiefupdate • Jun 26
AYTU: Higher Margins And Lower P/E Will Support Future Upside
Aytu BioPharma’s analyst price target has shifted from $12.50 to $14.50, with analysts pointing to updated assumptions for higher revenue growth, stronger profit margins, and a lower future P/E multiple as key drivers of the new outlook. What's in the News No recent company specific news items were identified for Aytu BioPharma from the provided sources.Analyseartikel • Dec 20
Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have had a really impressive month, gaining 28% after a shaky period...Analyseartikel • Nov 17
Aytu BioPharma, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) came out with its quarterly results last week, and we wanted to see how the...Analyseartikel • Oct 30
There's No Escaping Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Muted Revenues Despite A 27% Share Price Rise
Those holding Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares would be relieved that the share price has rebounded 27% in...Analyseartikel • Jul 29
Improved Revenues Required Before Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock's 25% Jump Looks Justified
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have continued their recent momentum with a 25% gain in the last month...Analyseartikel • May 14
We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation
Key Insights Aytu BioPharma will host its Annual General Meeting on 21st of May Total pay for CEO Josh Disbrow includes...Analyseartikel • May 04
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders are no doubt pleased to see that the share price has bounced 27% in...Analyseartikel • Jan 18
Aytu BioPharma, Inc. (NASDAQ:AYTU) Shares Fly 28% But Investors Aren't Buying For Growth
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders are no doubt pleased to see that the share price has bounced 28% in...Analyseartikel • Nov 15
Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32%
To the annoyance of some shareholders, Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares are down a considerable 32% in the...Analyseartikel • Nov 01
Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Jun 20
It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year
Key Insights Aytu BioPharma will host its Annual General Meeting on 26th of June Salary of US$590.0k is part of CEO...Analyseartikel • Jun 14
Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Feb 17
US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) just released its latest quarterly results and things are looking bullish. Results...Analyseartikel • Feb 16
Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have been powering on, with a gain of 25% in...Analyseartikel • Jan 23
Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Sep 29
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders have had their patience rewarded with a 59% share price jump in the...Seeking Alpha • Oct 13
Aytu stock falls amid suspending clinical programs to save costs
Aytu BioPharma (NASDAQ:AYTU) stock dipped ~5% on Oct. 13 after the company said it was indefinitely suspending certain clinical development programs, thus expecting to save over $20M. The suspension includes AR101/enzastaurin for treat Vascular Ehlers-Danlos Syndrome (VEDS), Healight, and NT0502. Aytu is expecting to generate positive quarterly adjusted EBITDA in H1 calendar year 2023. "This strategic realignment enables us to dedicate our resources to growing our prescription and consumer health segments. Coupled with the suspension of clinical development activities and continued execution against our previously planned $15 million cost cutting program, this shift enables the Company to achieve near-term positive Adjusted EBITDA," said Aytu CEO Josh Disbrow in an Oct. 13 press release. The company expects to provide a detailed financial outlook of its strategy at its quarterly investors call scheduled for mid-November.Seeking Alpha • Sep 27
Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M
Aytu BioScience press release (NASDAQ:AYTU): FQ4 GAAP EPS of -$0.49 misses by $0.12. Revenue of $27.45M (+16.9% Y/Y) beats by $1.95M. Cash and cash equivalents at the end of the fiscal year ended June 30, 2022 were $19.4 million. Subsequent to the end of the year, the Company raised $10.0 million in gross proceeds in a registered public offering. Prescription segment Adjusted EBITDA was a positive $1.1 million, while Consumer Health was $(2.1) million resulting in a combined Adjusted EBITDA of $(1.0) million for the Company's commercial business. This compares to Adjusted EBITDA of $(5.5) million for the Prescription segment and $(2.7) million for the Consumer Health segment in Q4 2021, resulting in a combined Adjusted EBITDA of $(8.2) million for the Company's commercial business. Shares +5.26%.Seeking Alpha • Sep 14
Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder
Aytu BioPharma (NASDAQ:AYTU) announced on Wednesday the addition of a fourth patent for AR101/Enzastaurin to treat Vascular Ehlers-Danlos Syndrome, rare genetic disorder treatment. The patent has an expiry date of September 2041. The company expects to advance the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023. "Adding this fourth patent to the portfolio deepens and broadens the intellectual property surrounding AR101/Enzastaurin for the treatment of inherited vascular disorders, including VEDS, for which we are advancing AR101 as an initial indication," the company said. Vascular Ehlers-Danlos syndrome (vEDS) is the most severe type of a hereditary disorder of the connective tissue. (AYTU) had risen 3.3% before the bell.Seeking Alpha • Aug 16
Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders
Aytu BioPharma (NASDAQ:AYTU) said the U.S. Patent and Trademark Office issued a patent, a first for AR101/Enzastaurin. The U.S. patent No. 11,273,148 titled 'Targeted Epigenetic Therapy for Inherited Aortic Aneurism Condition,' covers methods for the targeted epigenetic therapy of inherited aortic aneurysm and other diseases with altered regulation of TGFβ genes, including Ehlers-Danlos Syndrome, the company said in an Aug. 16 press release. Aytu added that it was the first issued patent supporting the portfolio and expires in August of 2038, if not extended. "This issued patent underpins the broad potential clinical application across numerous inherited vascular disorders, including vascular Ehlers-Danlos Syndrome ("VEDS"), for which we are advancing AR101 as an initial indication. We expect to progress the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023," said Aytu CEO Josh Disbrow. AYTU +0.59% to $0.29 premarket Aug. 16Seeking Alpha • Aug 09
Aytu BioPharma plunges on pricing $10M stock and warrants offering
Aytu BioPharma (NASDAQ:AYTU) priced its underwritten public offering of 21.5M shares to certain investors, pre-funded warrants to purchase 1.75M shares and accompanying warrants to purchase 23.2M shares,. The combined public offering price for each share of common stock and accompanying common warrant is $0.43 and combined offering price for each pre-funded warrant and accompanying common warrant is $0.429. Gross proceeds are expected to be ~$10M. Offer is expected to close on Aug.11. Net proceeds to be used for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome, for growth of the company's commercial business, and for working capital and general corporate purposes.Analyseartikel • May 19
Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00
It's been a pretty great week for Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders, with its shares surging 18% to...Analyseartikel • Sep 11
Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Stabiliteit en groei van betalingen
Dividenden ophalen
Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van AYTU in het verleden stabiel is geweest.
Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van AYTU zijn gestegen.
Dividendrendement versus markt
| Aytu BioPharma Dividendrendement versus markt |
|---|
| Segment | Dividendrendement |
|---|---|
| Bedrijf (AYTU) | n/a |
| Markt onderkant 25% (US) | 1.4% |
| Markt Top 25% (US) | 4.2% |
| Gemiddelde industrie (Pharmaceuticals) | 1.9% |
| Analist prognose (AYTU) (tot 3 jaar) | n/a |
Opmerkelijk dividend: Het dividendrendement van AYTU kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Hoog dividend: Het dividendrendement van AYTU kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Winstuitkering aan aandeelhouders
Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio AYTU te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat AYTU geen uitbetalingen heeft gerapporteerd.
Ontdek bedrijven met een sterk dividend
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/30 05:18 |
| Aandelenkoers aan het einde van de dag | 2026/06/30 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/06/30 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Aytu BioPharma, Inc. wordt gevolgd door 5 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Jeffrey Cohen | Ladenburg Thalmann & Company |
| Thomas Flaten | Lake Street Capital Markets, LLC |